Navigation Links
Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Date:9/6/2007

inical study performed at Wexham Park Hospital, Slough, UK in patients undergoing hysterectomy surgery were particularly encouraging in achieving the desired analgesic effect. In March 2007, Innocoll filed an IND and is planning to conduct a series of phase 2 clinical trials in the US commencing later this year.

About EUSA Pharma

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has 5 products on the market, including Erwinase(R) and Kidrolase(R) for the treatment of acute lymphoblastic leukemia, and Rapydan(TM), a rapid-onset anaesthetic patch. Supported by leading life science investors, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest, EUSA Pharma has raised over $225 million and completed three significant acquisitions since its founding in May 2006. Maintaining its focus on oncology, pain control and critical care, the company is currently seeking partners for the non-core development programs it gained as part of its recent acquisitions, in Alzheimer's disease, multiple sclerosis, anti-psychosis and inflammatory diseases. For more information, please visit http://www.eusapharma.com.

About Innocoll, Inc.

Innocoll is a privately held, specialty pharmaceutical company focused on surgical and dermatological products. It develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen- based technologies, CollaRx(R) and Liquicoll(R). Innocoll 's lead product, Gentamicin Surgical Implant for the treatment and prevention of surgical site infections, is approved for sale in 49 countries and entering phase 3 development in the US. Other late stage pharmaceutical products in Innocoll's development pipeline include CollaRx Gentamicin Top
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. GlaxoSmithKline Agrees To Settle Paxil Claims For $14 million
2. India and China Agrees to Promote Healthcare Jointly
3. China Agrees to Share Bird Flu Samples
4. Purdue Pharma Agrees to Pay $600 Million Fine for Misbranding Oxycontin
5. New spray gel heals surgical wounds
6. FDA approves surgical gel
7. Sleep apnoea linked to surgical risks
8. Lower surgical volume linked to higher death rate
9. Treatment Of Brain Aneurysms By A New Non-Surgical Approach
10. Complete Robotic Surgery To Revolutionize Surgical Treatment of Prostate Cancer
11. Indonesian boy with huge neck tumor was surgically removed
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Daniel K. Spiegelman Elected to Board of Directors of Omeros 2The Presidents Council on Physical Fitness and Sports Announces 2009 Lifetime Achievement Award Winners 49257 1The Presidents Council on Physical Fitness and Sports Announces 2009 Lifetime Achievement Award Winners 49257 2The Presidents Council on Physical Fitness and Sports Announces 2009 Lifetime Achievement Award Winners 49257 3Texas Institute for Surgery at Presbyterian Hospital of Dallas Introduces the First Wireless OR in DFW 49253 1Texas Institute for Surgery at Presbyterian Hospital of Dallas Introduces the First Wireless OR in DFW 49253 234 Outstanding Teachers and Schools Receive 2410 000 Amgen Award for Science Teaching Excellence 49248 134 Outstanding Teachers and Schools Receive 2410 000 Amgen Award for Science Teaching Excellence 49248 234 Outstanding Teachers and Schools Receive 2410 000 Amgen Award for Science Teaching Excellence 49248 334 Outstanding Teachers and Schools Receive 2410 000 Amgen Award for Science Teaching Excellence 49248 4